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Bile Salts in Control of Lipid Metabolism
2Chap
te
rPurpose of review: The view on bile salts has evolved over the 
years from being regarded as simple detergents that aid 
intestinal absorption of fat-soluble nutrients to being important 
hormone-like integrators of metabolism. This review provides an 
update	on	the	rapidly	developing	field	of	interactions	between	
bile salts and lipid metabolism, with a particular emphasis on 
the underlying mechanisms.
• 
Recent findings: The nuclear receptor farnesoid X receptor (FXR) 
plays major roles in bile salt-mediated signaling pathways. The 
recent	identification	of	novel	FXR	targets	and	factors	involved	
in FXR signaling highlights the interactions of bile acids with 
lipid metabolism. Exciting data have been reported on the use 
of	 intestine-specific	 FXR	 agonists	 as	 well	 as	 antagonists.	 In	
addition, encouraging results for treatment of hepatic steatosis 
obtained with obeticholic acid in the FLINT trial underline the 
therapeutic potential of bile salt signaling and metabolism for 
the treatment of lipid disorders.
Summary: Modulation of FXR activity appears to be a potent 
target, not only for improving bile salt homeostasis, but also to 
improve lipid metabolism. Depending on the metabolic context 









distinctly control metabolic homeostasis
• Intestinal	FXR	agonism	as	well	as	antagonism	may	prove	beneficial,	depending	
the metabolic context.
• FXR	and	TGR5	 in	part	mediate	 the	beneficial	effects	of	bariatric	surgery	 in	
rodents
• The	beneficial	 effects	of	FXR	activation	observed	 in	patients	with	NAFLD/







Bile Salts in Control of Lipid Metabolism
Introduction
Bile salts are synthesized in the liver from cholesterol via a multi enzyme pathway and are subsequently secreted into the canalicular 
space	between	hepatocytes.	Via	an	osmotic	effect	 they	subsequently	
drive	water	flow	leading	to	the	formation	of	bile.	In	mice	and	humans,	
bile is stored in the gallbladder. After each meal the gallbladder empties 
and bile salts enter the small intestine where they aid in absorption and 
transport of dietary lipids and fat-soluble vitamins.53 Besides their role 
in intestinal nutrient handling, bile salts have come forth as important 
regulators of metabolic pathways and energy metabolism. Because the 
concentration of bile salts in blood is highest after their reabsorption 
in the ileum, maximal signaling occurs when the food has passed 
the small intestine. Hence, postprandial signaling likely represents 
a major function of bile salts. Both, the nuclear receptor farnesoid X 
receptor (FXR) and G protein-coupled bile acid receptor 1 (TGR5),  are 
activated by bile acids and have been shown to regulate cholesterol 
and triglyceride metabolism, but also glucose metabolism and energy 
expenditure.1,54 All these processes are heavily regulated during the 
postprandial phase and bile salts play a role herein.2,55 Bile salts are 
known to regulate their own synthesis via a feedback mechanism 
under non-cholestatic conditions primarily involving intestinal 
FXR	 and	 its	 target	 gene	 fibroblast	 growth	 factor	 15/19	 (FGF15/19);	
for recent reviews see.56,57 FGF15 and FGF19 are mouse and human 
orthologs, respectively and are secreted into the portal circulation by 
enterocytes in response to intestinal FXR activation.39 By binding to the 
fibroblast	growth	factor	receptor	4	(FGFR4)/β-klotho	receptor	complex	
in hepatocytes, FGF15/19 inhibits bile salt synthesis.38 However, the 
mechanistic details of this signaling pathway are, as yet, incompletely 
characterized. In mice, FXR activation inhibits the classical (CYP7A1-
mediated) pathway more than acidic (CYP27A1-mediated) bile salt 
synthesis. Together with a strong inhibition of Cyp8b1 this leads to an 
increased CDCA/CA ratio (a schematic overview is given in Figure 1). 
In mice but not in humans, chenodeoxycholate (CDCA) is rapidly 
converted into muricholate (MCA) which is very hydrophilic compared 
to the rather hydrophobic CDCA. This has major consequences for 
the physical chemical properties of the bile salt pool. Hydrophilic bile 
salts are less potent in solubilizing cholesterol and a hydrophilic bile 
salt pool therefore translates into reduced cholesterol absorption.58 In 
mice, FXR agonist treatment could therefore be presumed to increase 
fecal neutral sterol excretion. On the other hand, in humans FXR 
agonism could be anticipated to generate a more hydrophobic bile salt 
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pool leading to increased cholesterol absorption, reduced fecal neutral 
sterol excretion, and an increase in plasma LDL cholesterol.
Increased	 circulating	 bile	 salts	 have	 been	 linked	 to	 the	 beneficial	
metabolic changes occurring in patients following bariatric surgery, 
i.e. reduced body weight and improved glucose tolerance.59 These 
observations evoked a lot of interest in the metabolism-governing 
capabilities of bile salts.60-62 In this review we will discuss the most 
recent progress in bile salt research, with a special emphasis on 
the interaction of bile salts with lipid and energy metabolism via 
FXR-mediated signaling. For a more comprehensive background 
on bile salt metabolism, the reader is referred to recent excellent 
reviews.63,64 
FXR isoform-specific actions 
Knockout mice of the nuclear receptor FXR have revealed a critical role of FXR on bile salt and lipid homeostasis.65 FXR KO mice are 
characterized by elevated plasma bile salt, triglyceride and cholesterol 
levels as well as increased hepatic triglyceride and cholesterol levels. 
Although FXR is expressed in various cell types, highest expression is 
found in hepatocytes and enterocytes.66	Four	different	FXR	isoforms	
have	 been	 described,	 which	 result	 from	 different	 promotors	 and	
alternative splicing.67	FXRα1	and	FXRα3	contain	4	extra	amino	acids	
in the hinge region of the protein and are transcriptionally less active 
compared	to	FXRα2	and	FXRα4,	which	differ	at	the	amino	terminus.66 
Delineation	 of	 the	 specific	 functionality	 of	 the	 FXR	 isoforms	 is	 still	
in	 its	 infancy.	 Yet,	 Correia	 et	 al.	 studied	 the	 differences	 between	
FXR	isoforms	and	showed	that	different	FXR	isoforms	differentially	




FXRα4	are	able	 to	 reduce	hepatic	 lipid	accumulation	and	 increased	
insulin sensitivity.68 Using adeno-associated virus (AAV)-mediated 
expression	in	FXR-null	mice,	Boesjes	et	al.	demonstrated	that	FXRα2	
and	 FXRα4	 have	 differential	 effects	 on	 lipoprotein	 and	 bile	 salt	
metabolism.69	 Reintroduction	 of	 FXRα2	 reduced	 plasma	 cholesterol	
to	wild	type	 levels,	whereas	reintroduction	of	FXRα4	resulted	in	an	
effect	that	was	much	less	pronounced.	FXRα2	and	FXRα4	differentially	
impacted on the expression of genes involved in bile acid synthesis. In 
particular,	FXRα2	reduced	the	expression	of	cytochrome	P450,	family	
8,	 subfamily	b,	 polypeptide	 1	 (CYP8B1)	 relative	 to	 FXRα4.	 In	mice,	
reduced CYP8B1 activity results in a more hydrophilic bile salt pool, 
due to the formation of muricholic acids (MCA). Of special interest in 
this	respect,	v-maf	avian	musculoaponeurotic	fibrosarcoma	oncogene	
homolog	G	(MAFG)	was	recently	identified	as	a	downstream	target	of	
FXR. This transcriptional repressor was found to reduce Cyp8b1 and 
Figure 1: schematic overview of the regulation of bile acid synthesis by bile acids
Bile saltss are synthesized from cholesterol in the liver via the classical (Cyp7a1-mediated) or acidic 
(Cyp27a1-mediated) pathway. Bile salts are secreted into the bile and stored in the gallbladder. After 
a meal, the gallbladder empties and bile salts enter the small intestine via the bile duct. In the ileum, 
bile salts are reabsorbed and bind to the nuclear receptor FXR. Activation of FXR by bile salts leads 
to secretion of FGF15/19 from the enterocyte into the portal circulation. FGF15/19 inhibits cyp7a1 via 
binding to the  FGFR4/β-Klotho receptor complex.
also other genes involved in bile salt metabolism such as Cyp7b1 and 
Cyp27a1.70 Of note, expression of the main rate controlling enzyme 
in	 bile	 salt	 synthesis,	 Cyp7a1,	 was	 not	 affected	 by	 MAFG.	 Hence,	
overexpression of MAFG in mice induced a shift in bile salt species 
distribution	but	had	no	 effect	 on	 the	 size	 of	 the	 bile	 salt	 pool.	 FXR	
isoform-specific	regulation	of	MAFG	has	thus	far	not	been	investigated,	
but would certainly be worthwhile to explore.
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Bile salt mediated crosstalk between liver and intestine
The recently established role of protein tyrosine phosphatase, non-receptor type 11 (SHP2/PTPN11) adds an extra layer 
of complexity to FXR-regulated bile salt metabolism. SHP2 is a 
non-receptor tyrosine phosphatase that acts downstream of FGFR4 
and is thereby involved in FGF15/19 signaling. Hepatic ablation of 
SHP2 causes upregulation of bile salt synthesis.71 Remarkably, the 
increased concentration of bile salts in plasma and liver failed to 
activate hepatic FXR, suggesting that SHP2 is not only involved in 
FGFR4-mediated	signaling	but	also	in	a	as	yet	unidentified	pathway	
that couples intestinal FGF15/19 signaling to hepatic FXR activation. 
The reverse also appears to take place. Activation of FXR in the liver 
was reported to sensitize hepatocytes for intestinal FGF15/19 signaling 
by	 increasing	 β-Klotho	 levels.72	 This	 finally	 leads	 to	 enhanced	
responsiveness to FGF15/19. Combined, these data clearly point 
out that the liver and intestine act in a concerted manner to provide 
accurate feedback on bile acid synthesis. FGF15/19 production by the 
intestine was recently reported to be regulated by the deacetylase 
sirtuin 1 (SIRT1).73 FXR as well as the apical sodium-dependent bile 
acid transporter (ASBT/SLC10A2) are direct target genes of hepatocyte 
nuclear	factor	1α	(HNF-1α).	Acetylation	of	the	dimerization	cofactor	
of	 HNF1α,	 DCoH2,	 reduces	 binding	 of	 the	 HNF1α	 dimer	 to	 the	
promoter of these genes. By deacetylating DCoH2, SIRT1 can exert a 
major	influence	on	bile	salt	homeostasis73.73 In line, the authors showed 
that intestinal deletion of SIRT1 leads to reduced ileal uptake of bile 
salts and reduced expression of Fgf15/19, leading to increased bile salt 
synthesis in the liver. When challenged with a 0.5% cholic acid diet, 
intestinal SIRT1-KO mice displayed lower liver damage markers and 
had reduced hepatic cholesterol levels. 
Intestinal microbiota and bile salt signaling
Intestinal microbiota converts primary bile salts into secondary bile salts which in most cases increases the hydrophobicity of bile salts. 
Accordingly,	microbiota	 affects	FXR	as	well	 as	TGR5	 signaling	 and	
hence impact on lipid and energy metabolism.74 The primary bile salt 
chenodeoxycholic acid (CDCA) is the most potent endogenous FXR 
agonist whereas its bacterial derivative, lithocholic acid (LCA), is 
a much less potent inducer of FXR activation.75 On the other hand, 
bacterial conversion of cholic acid (CA) to deoxycholic acid (DCA) 
results in a secondary bile salt that is a more potent FXR agonist, at 
least under in vitro conditions.76,77 Song and coworkers assessed the 
effects	of	a	various	bile	salt	species	in vivo by adding them to the diet in 
different	concentrations.78	They	observed	remarkable	differences	in	the	
responses of the liver and intestine to the bile salts tested. Intestinal FXR 
appeared to be more activated by CA and DCA compared to CDCA. 
This is in apparent contrast with the data obtained from cell culture 
experiments and underlines that in vitro data do not always accurately 
reflect	the	in vivo situation. Interestingly, hydrophilic bile salts such as 
tauro-ß-muricholic acid have been reported to act as FXR antagonists.79 
Moreover, FXR activity was recently shown to be modulated directly 
by bacterial metabolites.80 Administration of culture supernatants 
of E. limosum and B. dorei increased FXR activity and expression of 
FXR target genes in diet-induced obesity (DIO) mice. Microbiota also 
impact bile salt re-absorption by regulating the expression of Asbt. 
Conceivably this is mediated via induction of the transcription factor 
GATA binding protein 4 (GATA4), which negatively regulates this bile 
salt transporter.81
Bile acids mediate beneficial metabolic effects associated with 
bariatric surgery
Bariatric	surgery	has	been	shown	to	influence	bile	salt	metabolism	and changes gut microbiota.64 In a study of Ryan et al. FXR has 
been	suggested	to	mediate	the	beneficial	metabolic	effects	induced	by	
vertical sleeve gastrectomy (VSG), including reduction in body weight, 
decreased hepatic steatosis and improvement of glucose tolerance.59 
VSG	 in	 DIO	 FXR-null	 mice	 resulted	 in	 considerably	 attenuated	
improvements compared to their wildtype controls.59 However, the 
severe surgery-induced weight loss in the FXR-null mice made these 
results	difficult	to	interpret.	A	similar	experiment	has	been	performed	
in TGR5-null mice.82 VSG in high fat diet fed TGR5-null mice resulted 
in impaired improvements in glucose tolerance, insulin signaling and 
hepatic	 inflammation,	 suggesting	 that	 also	 TGR5	 contributes	 to	 the	
beneficial	effects	on	glucose	metabolism	after	VSG.	Interestingly,	the	
beneficial	 effect	 of	 bariatric	 surgery	 in	mice	 could	 be	mimicked	 by	
just diverting bile entry from the duodenum to the ileum.83 After this 
surgical procedure, mice display improvements in glucose and lipid 
metabolism, body weight, hepatic steatosis and adiposity. Ileal bile 
entry induced an increase in plasma bile salt levels and a concomitant 
decrease	 in	 plasma	 triglycerides	 and	 circulating	 free	 fatty	 acids.	
Remarkably, Fgf15 expression in the ileum decreased. However, this 
might be explained by an increase in the concentration of tauro-ß-
muricholic acid, which may function as an FXR antagonist. Moreover, 
the	beneficial	effects	after	bariatric	surgery	could	in	part	be	due		by	an	
increase in plasma levels of the gut hormone glucagon-like peptide 
1 (GLP-1) as reported by Osto et al.84  GLP-1 secretion peaks shortly 
after a meal and this signal maybe be induced by an interaction of bile 
salts with the neuroendocrine L-cells residing in the small intestine, 
however, the mechanism via wich bile salts exert control on GLP-1 
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is	 a	matter	 of	 debate.	 The	 hormone	 has	many	 beneficial	 properties	
including regulatory actions on glucose metabolism, inhibition of 
gastric emptying and stimulation of satiety.85
Intestinal bile salt signaling and energy expenditure
Jiang et al. demonstrated that glycine-ß-muricholic acid (Gly-MCA) functioned as an intestine-selective FXR-antagonist and prevented 
mice from high-fat diet (HFD)-induced obesity, insulin resistance and 
hepatic steatosis.86 Treatment of mice with Gly-MCA induced browning 
of subcutaneous adipose tissue and increased energy expenditure, 
conceivably resulting from reduced intestinal biosynthesis of ceramides. 
Paradoxically, very similar results were obtained in mice treated with 
the	 intestine-specific	 FXR	 agonist	 fexaramine.	 Notwithstanding,	
the intestine-restricted FXR activation improved browning of white 
adipose tissue and led to a striking 1.5 degrees increased body 
temperature, resulting in increased energy expenditure, protection 
against diet-induced obesity and insulin resistance, and reduced 
plasma cholesterol levels.87 Plasma triglycerides were, however, not 
affected.	 Data	 obtained	 using	 fexaramine-treated	 TGR5-KO	 mice	
suggested that the observed improvement of insulin sensitivity and 
antilipogenic	 effects	 of	 fexaramine	 on	 the	 liver	were	mainly	due	 to	
increased signaling via TGR5. Although fexaramine cannot activate 
TGR5, this receptor is known to be activated by hydrophobic bile 
salts, most potently by LCA.54 The authors reported that fexaramine 
treatment resulted in high plasma concentrations of LCA. This is a 
remarkable observation because intestinal absorption of this secondary 
bile salt is very poor and high plasma concentrations of LCA have 
not been reported before in DIO mouse models. Moreover, high LCA 
levels were not observed in a genetic model of intestine-selective FXR 
activation.88 It would therefore be of interest to explore whether the 
high	LCA	levels	 in	response	to	fexaramine	are	a	compound-specific	
effect,	e.g.	mediated	by	a	particular	FXR-isoform.
FXR mediated lipid-lowering strategies
An interesting link between FXR activity and triglyceride homeostasis has been reported by Li and coworkers. They 
observed that hepatic knock-down of a long non-coding RNA, liver-
specific	triglyceride	regulator	(lncLSTR),	induces	a	reduction	of	plasma	
triglycerides in mice.89 lncLSTR depletion increased apolipoprotein 
CII (ApoC2) expression which acts as an activator of lipoprotein lipase 
(LPL), resulting in reduced plasma triglycerides levels. Interestingly, 
the induction of ApoC2 was found to be controlled by a FXR-mediated 
pathway. A complex of lncLSTR and TAR DNA Binding Protein 
(TDP-43), a RNA and DNA binding protein, regulates Cyp8b1 promoter 
activity. In absence of lncLSTR, Cyp8b1 expression is inhibited. This 
causes a change in bile salt species distribution, i.e. an increased MCA/
CA	ratio.	In	contrast	to	the	FXR-antagonistic	properties	attributed	to	
MCA, Li et al.	report	that	muricholates	specifically	promote	expression	
of	ApoC2	in	a	FXR-dependent	manner.	Clearly	this	remarkable	finding	
calls for further investigation. For example, it would be appealing 
to	 explore	 whether	 ApoC2	 expression	 is	 controlled	 by	 a	 specific	
FXR isoform. Previous studies in mice have demonstrated that FXR 
activation ameliorates hepatic steatosis in animal models.55	This	effect	
has	 now	 been	 confirmed	 in	 humans.90 A double blind randomized 
trial with the FXR agonist obeticholic acid (INT-747) resulted in 
improved steatosis in the treated individuals.90 In contrast to what was 
found in animal models,91 obeticholic acid increased plasma levels of 
low-density lipoprotein cholesterol (LDL) cholesterol. The mechanism 
underlying	this	undesirable	effect	remains,	however,	to	be	elucidated.	
One may speculate that, in addition to the FXR-induced decrease in 
cholesterol catabolism because of reduced bile salt synthesis, major 
differences	in	bile	salt	and	lipoprotein	metabolism	(for	the	latter	see	
review92) between humans and rodents may be a primary underlying 
reason. In contrast to what is usually observed in mice upon FXR 
activation,93	 obeticholic	 acid	 did	 not	 significantly	 impact	 plasma	
triglycerides.	Thus,	also	this	aspect	of	FXR	activation	appears	to	differ	
between mice and men. 
Bile salts and cholesterol metabolism
The group of Hazen lately published several landmark papers concerning the metabolic fate of tertiary amines after bacterial 
metabolism (see review94). The main product, trimethylamine (TMA), 
is converted into trimethylamine N-oxide (TMAO) primarily by 
hepatic	 flavin	 monooxygenase	 3	 (FMO3).95 This TMA metabolite 
increases atherosclerosis in mice by an as yet unknown mechanism.96 
FMO3 is a FXR target gene97, providing a potential link between bile 
salts and TMAO formation. In addition, a direct link between Fmo3 
expression and cholesterol homeostasis was recently reported in mice.98 
Knockdown of FMO3 in mice reduced intestinal cholesterol absorption 
as well as the hepatic cholesteryl ester content and biliary cholesterol 
secretion. Moreover, FMO3 knockout mice exhibited a reduced bile 
salt pool size, likely resulting from decreased expression on Cyp7a1 
and Cyp8b1.	 Interestingly,	 the	authors	 identified	hepatic	FMO3	as	a	
negative regulator of the transintestinal cholesterol excretion (TICE) 
pathway. Although FMO3 would provide a possible link between bile 
acids and this emerging cholesterol removal pathway, details of this 
apparent connection remain to be elucidated. 
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During the last two years, substantial progress has been made in understanding the mechanisms via which bile salts regulate 
both lipid and energy homeostasis. A complex signal transduction 
pathway is emerging, particularly around FXR. This nuclear receptor 
more and more emerges as an appealing target for treatment of several 
clinical and subclinical manifestations associated with the metabolic 
syndrome. It has to be kept in mind, however, that chronic activation 
of	 FXR	 has	 revealed	 some	 undesirable	 side	 effects	 such	 as	 hepatic	
toxicity, growth retardation, and neonatal lethality.99 Of note, the 
neonatal lethality in constitutively active FXR mice can be overcome 
by vitamin supplementation, suggesting that suppression of bile salt 
synthesis and resultant vitamin deprivation may (partly) underlie the 
observed	 adverse	 effects	 associated	with	 chronic	 FXR	 activation.	 In	
that case, vitamin supplementation could potentially overcome those 
detrimental	 effects,	which	would	make	 clinical	use	of	FXR	agonists	
more applicable.
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